Zealand Pharma Signs AI Protein Therapeutics Collaboration With Generate
The multi-target collaboration covers obesity and metabolic diseases. Generate will receive $30 million upfront and up to $35 million in early preclinical milestones, with up to approximately $1.2 billion in total milestones.
Zealand Pharma entered a multi-target collaboration with Generate Biomedicines to design AI-engineered protein therapeutics for obesity and metabolic diseases. Generate will receive $30M up front and could earn up to $35M in early preclinical milestones. 2B in total milestones, plus tiered r…